Back to announcements list
Notice of Interim Report
RNS Number : 0932J
RTW Venture Fund Limited
19 August 2021
 

LEI: 549300Q7EXQQH6KF7Z84

19 August 2021

RTW Venture Fund Limited

Notice of Interim Report

RTW Venture Fund Limited (the "Company") advises that it will publish its Interim Report for the six months ended 30 June 2021 (the "Interim Report") on 16 September 2021.

A conference call for analysts and sales teams will be held at 2 pm BST / 9 am EST on the day. To register for the event please RSVP to [email protected].

For Further Information

RTW Investments, LP                                        +1 (646) 343 9280
Stephanie Sirota, Chief Business Officer
Alexandra Taracanova, PhD, Director of Investor Relations

Julia Enright, Business Development Associate

 

Buchanan                                                          +44 (0)20 7466 5000
Charles Ryland

Henry Wilson

George Beale

 

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORFLFVRTFITLIL